Fewer high school students are vaping this year, the government reported Thursday.
In a survey, 10% of high school students said they had used electronic cigarettes in the previous month, down from 14% last year.
Use of any tobacco product — including cigarettes and cigars — also fell among high schoolers, according to the Centers for Disease Control and Prevention report.
“A lot of good news, I’d say,” said Kenneth Michael Cummings, a University of South Carolina researcher who was not involved in the CDC study.
Among middle school students, about 5% said they used e-cigarettes. That did not significantly change from last year’s survey.
This year's survey involved more than 22,000 students who filled out an online questionnaire last spring. The agency considers the annual survey to be its best measure of youth smoking trends.
Why the drop among high schoolers? Health officials believe a number of factors could be helping, including efforts to raise prices and limit sales to kids by raising the legal age to 21.
“It’s encouraging to see this substantial decrease in e-cigarette use among high schoolers within the past year, which is a win for public health,” said Brian King, the Food and Drug Administration's tobacco center director.
The FDA has authorized a few tobacco-flavored e-cigarettes intended to help adult smokers cut back but has struggled to stop sales of illegal products.
Other key findings in the report:
— Among students who currently use e-cigarettes, about a quarter said they use them every day.
— About 1 in 10 middle and high school students said they recently had used a tobacco product. That translates to 2.8 million U.S. kids.
— E-cigarettes were the most commonly used kind of tobacco product, and disposable ones were the most popular with teens.
— Nearly 90% of the students who vape used flavored products, with fruit and candy flavors topping the list.
In 2020, FDA regulators banned those teen-preferred flavors from reusable e-cigarettes like Juul and Vuse, which are now only sold in menthol and tobacco. But the flavor restriction didn’t apply to disposable products, and companies like Elf Bar and Esco Bar quickly stepped in to fill the gap.
The growing variety in flavors like gummy bear and watermelon has been almost entirely driven by cheap, disposable devices imported from China, which the FDA considers illegal. Those products now account for more than half of U.S. vaping sales, according to government figures.
In the latest survey, about 56% of teens who vape said they used Elf Bar, trailed by Esco Bar and Vuse, which is a reusable e-cigarette made by R.J. Reynolds. Juul, the brand widely blamed for sparking the recent spike in teen vaping, was the fourth most popular brand, used by 16% of teens.
The FDA tried to block imports of both Elf Bar and Esco Bar in May, but the products remain widely available. Elf Bar has thwarted customs officials by changing its brand name, among other steps designed to avoid detection
On Thursday, the FDA announced another round of fines against 20 stores selling Elf Bar products. The agency has sent more than 500 warning letters to retailers and manufacturers of unauthorized e-cigarettes over the past year, but those citations are not legally binding and are sometimes ignored.
In the latest report, the CDC highlighted one worrisome but puzzling finding. There was a slight increase in middle school students who said they had used at least one tobacco product in the past month, while that rate fell among high school students. Usually, those move in tandem, said Kurt Ribisl, a University of North Carolina researcher. He and Cummings cautioned against making too much of the finding, saying it might be a one-year blip.
Perrone reported from Washington.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
The FDA has granted emergency use authorization to Pfizer's pill to treat covid-19. The treatment, called Paxlovid, is the first antiviral covid-19 pill that people can take at home.
Pfizer says the pill can reduce the risk of severe illness by 90 percent and is intended for people at high risk for severe disease, including those over 65, people with obesity, diabetes, or a weakened immune system. Professor Peter Pitts, Founder, Center for Medicine in the Public Interest & Former FDA Associate joined Wake Up with Cheddar to discuss.
Ahead of a four day week for the markets due to the upcoming Christmas holiday, investors hoping for a quiet end to the year, or even a Santa Claus rally, may not be in luck. Investors are still digesting the latest from the Fed regarding a quicker than expected taper, as well as ever increasing blow back as the Omicron variant spreads. Octavio Marenzi, CEO of Opimas LLC, explains why the markets have been so volatile ever since the emergence of the latest variant and what to expect going forward into 2022.
Carlo and Baker cover the heartening news on the Covid front ahead of the holiday, plus President Biden punting student loan repayments again, a new space telescope and Love, Hate, Ate: Christmas Eve Eve Edition!
Pfizer, one of the makers of a currently available COVID-19 vaccine, has taken another critical step forward in combatting the pandemic by getting regulatory approval for Paxlovid, a pill treatment rather than IV or injection as others have been. Dr. Purvi Parikh, an immunologist with the Allergy and Asthma Network, spoke to Cheddar about the ramifications of the authorization. "This is huge, especially because we know early treatment does keep people out of the hospital, especially with this antiviral," Parikh said. "The fact that people can start a regimen at home so they don't have to leave and further expose others is a big breakthrough." She also explained how the drug is a combination of two antiviral medications that are not without its risks but should be safe over the short term.
This year's worldwide semiconductor shortage limited the supply of everything from new cars to smartphones; and now, many in the chip industry expect the shortage to continue deep into 2022, and maybe even 2023. Semiconductor senior research analyst for Robert W. Baird & Co., Tristan Gerra, joins Cheddar News' Closing Bell to discuss.
Direct health care company Nomi Health recently raised $110 million in a Series A round. Nomi Health lets public and private organizations directly purchase healthcare at reduced costs, and pay providers in real-time. It also delivers healthcare directly to under-served communities via its fleet of mobile care units, which the company says is the largest in the country. Nomi Health says its mission is to improve the health care experience for all Americans. Nomi Health CEO Mark Newman joined Cheddar News' Closing Bell to discuss.
The airline industry says it is contending with staff shortages that threaten to hamper operations amid the COVID resurgence, andDelta Airlines CEO Ed Bastian called on the CDC to revise its guidance for vaccinated workers who test positive from a 10-day quarantine to just five. Chuck Liberman, chief investment officer and managing partner at Advisors Capital Management LLC, joined Cheddar to talk about the current guidance on isolation and why he believes the omicron variant calls for more relaxed guidance given its reportedly mild symptoms.
The boys discuss President Biden's plans to send out free rapid tests as the testing supply chain starts to buckle ahead of the holidays. Also, why aren't Americans having more babies, and The Matrix returns.
NASA is launching its new generation of space telescopes just before Christmas. The James Webb Space Telescope, set to launch on December 24th, will succeed the Hubble space telescope as the world's most powerful complex space observatory. The project has been 30 years in the making and is one of the most highly anticipated space science missions of the 21st century. Klaus Pontoppidan, astronomer and JWST Project Scientist at the Space Telescope Science Institute joined Cheddar's Opening Bell to discuss.
With Omicron becoming the dominant COVID-19 variant in the U.S., President Joe Biden announced that he will make 500 million rapid tests available to Americans in January 2022. Cheddar News speaks with Dr. Shereef Elnahal, President and CEO of University Hospital why testing is key to combatting the spread of the virus.
